Elevation Capital Expenditures vs Stock Based Compensation Analysis

ELEV Stock

USD 0.56 0.02 3.52%

Elevation Oncology financial indicator trend analysis is much more than just examining Elevation Oncology latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Elevation Oncology is a good investment. Please check the relationship between Elevation Oncology Capital Expenditures and its Stock Based Compensation accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elevation Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.

Capital Expenditures vs Stock Based Compensation

Capital Expenditures vs Stock Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Elevation Oncology Capital Expenditures account and Stock Based Compensation. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Elevation Oncology's Capital Expenditures and Stock Based Compensation is -0.49. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of Elevation Oncology, assuming nothing else is changed. The correlation between historical values of Elevation Oncology's Capital Expenditures and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Elevation Oncology are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Capital Expenditures i.e., Elevation Oncology's Capital Expenditures and Stock Based Compensation go up and down completely randomly.

Correlation Coefficient

-0.49

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Elevation Oncology to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Elevation Oncology operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most indicators from Elevation Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Elevation Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elevation Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Elevation Stock please use our How to Invest in Elevation Oncology guide.At this time, Elevation Oncology's Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to climb to 0.02 in 2024, whereas Tax Provision is likely to drop slightly above 26 K in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	18K	27K	39K	27.2K
Cost Of Revenue	18K	27K	39K	27.2K

Reconciled Depreciation Cost Of Revenue

Elevation Oncology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Other Liab	Non Currrent Assets Other	Other Assets	Non Current Liabilities Other	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total
Total Assets		0.73	0.84	0.85	0.85	-0.8	-0.71	0.74	0.96	1.0	0.35	0.41	0.94	0.57	0.51	0.87	1.0	1.0	-0.78	0.54	0.26	-0.78	0.15	0.41	0.55	0.37
Other Current Liab	0.73		0.94	0.61	0.61	-0.28	-0.8	0.65	0.52	0.72	0.27	0.26	0.65	0.76	0.39	0.73	0.73	0.69	-0.87	0.85	0.79	-0.87	0.75	0.32	0.8	0.3
Total Current Liabilities	0.84	0.94		0.64	0.63	-0.52	-0.69	0.84	0.72	0.84	0.11	0.43	0.69	0.59	0.56	0.71	0.84	0.81	-0.78	0.67	0.71	-0.78	0.61	0.17	0.62	0.29
Total Stockholder Equity	0.85	0.61	0.64		1.0	-0.72	-0.58	0.5	0.82	0.85	0.28	-0.13	0.93	0.58	-0.02	0.98	0.85	0.85	-0.71	0.41	0.17	-0.71	-0.03	0.34	0.43	0.27
Net Tangible Assets	0.85	0.61	0.63	1.0		-0.72	-0.58	0.5	0.82	0.84	0.29	-0.13	0.93	0.57	-0.02	0.98	0.85	0.85	-0.7	0.41	0.17	-0.7	-0.04	0.34	0.43	0.25
Net Debt	-0.8	-0.28	-0.52	-0.72	-0.72		0.17	-0.74	-0.93	-0.81	0.05	-0.32	-0.73	-0.01	-0.38	-0.63	-0.81	-0.82	0.27	0.04	0.05	0.27	0.34	0.0	0.02	0.0
Retained Earnings	-0.71	-0.8	-0.69	-0.58	-0.58	0.17		-0.26	-0.5	-0.7	-0.76	-0.27	-0.74	-0.96	-0.36	-0.72	-0.71	-0.7	0.98	-0.92	-0.33	0.98	-0.53	-0.79	-0.93	-0.68
Accounts Payable	0.74	0.65	0.84	0.5	0.5	-0.74	-0.26		0.73	0.75	-0.22	0.53	0.53	0.08	0.64	0.51	0.75	0.72	-0.36	0.27	0.58	-0.36	0.28	-0.18	0.22	-0.16
Cash	0.96	0.52	0.72	0.82	0.82	-0.93	-0.5	0.73		0.96	0.2	0.38	0.89	0.36	0.47	0.79	0.96	0.97	-0.58	0.27	0.07	-0.58	-0.1	0.25	0.29	0.31
Cash And Short Term Investments	1.0	0.72	0.84	0.85	0.84	-0.81	-0.7	0.75	0.96		0.34	0.41	0.94	0.56	0.51	0.87	1.0	1.0	-0.77	0.53	0.26	-0.77	0.14	0.39	0.54	0.36
Common Stock Shares Outstanding	0.35	0.27	0.11	0.28	0.29	0.05	-0.76	-0.22	0.2	0.34		0.19	0.52	0.72	0.18	0.4	0.35	0.37	-0.65	0.67	-0.21	-0.65	0.08	1.0	0.76	0.53
Non Current Liabilities Total	0.41	0.26	0.43	-0.13	-0.13	-0.32	-0.27	0.53	0.38	0.41	0.19		0.17	0.01	0.99	-0.06	0.41	0.4	-0.18	0.25	0.13	-0.18	0.24	0.19	0.25	0.14
Other Current Assets	0.94	0.65	0.69	0.93	0.93	-0.73	-0.74	0.53	0.89	0.94	0.52	0.17		0.66	0.27	0.95	0.94	0.95	-0.81	0.56	0.11	-0.81	0.01	0.57	0.6	0.38
Other Stockholder Equity	0.57	0.76	0.59	0.58	0.57	-0.01	-0.96	0.08	0.36	0.56	0.72	0.01	0.66		0.1	0.71	0.57	0.56	-0.96	0.9	0.34	-0.96	0.54	0.76	0.91	0.69
Total Liab	0.51	0.39	0.56	-0.02	-0.02	-0.38	-0.36	0.64	0.47	0.51	0.18	0.99	0.27	0.1		0.06	0.51	0.5	-0.29	0.34	0.25	-0.29	0.32	0.19	0.33	0.16
Net Invested Capital	0.87	0.73	0.71	0.98	0.98	-0.63	-0.72	0.51	0.79	0.87	0.4	-0.06	0.95	0.71	0.06		0.87	0.87	-0.82	0.59	0.28	-0.82	0.13	0.46	0.6	0.32
Total Current Assets	1.0	0.73	0.84	0.85	0.85	-0.81	-0.71	0.75	0.96	1.0	0.35	0.41	0.94	0.57	0.51	0.87		1.0	-0.78	0.54	0.26	-0.78	0.15	0.41	0.55	0.37
Net Working Capital	1.0	0.69	0.81	0.85	0.85	-0.82	-0.7	0.72	0.97	1.0	0.37	0.4	0.95	0.56	0.5	0.87	1.0		-0.76	0.51	0.21	-0.76	0.1	0.42	0.53	0.37
Other Liab	-0.78	-0.87	-0.78	-0.71	-0.7	0.27	0.98	-0.36	-0.58	-0.77	-0.65	-0.18	-0.81	-0.96	-0.29	-0.82	-0.78	-0.76		-0.9	-0.42	1.0	-0.53	-0.7	-0.9	-0.61
Non Currrent Assets Other	0.54	0.85	0.67	0.41	0.41	0.04	-0.92	0.27	0.27	0.53	0.67	0.25	0.56	0.9	0.34	0.59	0.54	0.51	-0.9		0.57	-0.9	0.73	0.7	0.99	0.41
Other Assets	0.26	0.79	0.71	0.17	0.17	0.05	-0.33	0.58	0.07	0.26	-0.21	0.13	0.11	0.34	0.25	0.28	0.26	0.21	-0.42	0.57		-0.42	0.86	-0.17	0.48	-0.15
Non Current Liabilities Other	-0.78	-0.87	-0.78	-0.71	-0.7	0.27	0.98	-0.36	-0.58	-0.77	-0.65	-0.18	-0.81	-0.96	-0.29	-0.82	-0.78	-0.76	1.0	-0.9	-0.42		-0.53	-0.7	-0.9	-0.61
Intangible Assets	0.15	0.75	0.61	-0.03	-0.04	0.34	-0.53	0.28	-0.1	0.14	0.08	0.24	0.01	0.54	0.32	0.13	0.15	0.1	-0.53	0.73	0.86	-0.53		0.11	0.64	0.23
Common Stock	0.41	0.32	0.17	0.34	0.34	0.0	-0.79	-0.18	0.25	0.39	1.0	0.19	0.57	0.76	0.19	0.46	0.41	0.42	-0.7	0.7	-0.17	-0.7	0.11		0.78	0.55
Property Plant Equipment	0.55	0.8	0.62	0.43	0.43	0.02	-0.93	0.22	0.29	0.54	0.76	0.25	0.6	0.91	0.33	0.6	0.55	0.53	-0.9	0.99	0.48	-0.9	0.64	0.78		0.43
Short Long Term Debt Total	0.37	0.3	0.29	0.27	0.25	0.0	-0.68	-0.16	0.31	0.36	0.53	0.14	0.38	0.69	0.16	0.32	0.37	0.37	-0.61	0.41	-0.15	-0.61	0.23	0.55	0.43

Click cells to compare fundamentals

Elevation Oncology Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Elevation Stock Analysis

When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Elevation Capital Expenditures vs Stock Based Compensation Analysis

Capital Expenditures vs Stock Based Compensation

Capital Expenditures vs Stock Based Compensation Correlation Analysis

Correlation Coefficient

Capital Expenditures

Stock Based Compensation

Elevation Oncology fundamental ratios Correlations

Elevation Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Elevation Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments

Non Current Liabilities Other	- 0.96	Other Stockholder Equity
Other Liab	- 0.96	Other Stockholder Equity
Other Stockholder Equity	- 0.96	Retained Earnings
Property Plant Equipment	- 0.93	Retained Earnings
Cash	- 0.93	Net Debt
Non Currrent Assets Other	- 0.92	Retained Earnings